GAO Maps Implantable Device Trends In Medicare
This article was originally published in The Gray Sheet
Executive Summary
Ortho procedures were associated with increased admission rates but shorter lengths of stay and more home-based recovery in recent years. Cardiac implants show a different picture, with a shift to outpatient procedures and more use by sicker patients, GAO found.
You may also be interested in...
House Adds Momentum, But Big Barriers To Device Tax Repeal Remain
Killing the 2.3% excise tax on U.S. device sales before it takes effect in January would be a major victory for the industry, but with opposition from the Senate and White House, achieving repeal remains a steep climb at best.
GAO Report Renews Debate Over Device Price Confidentiality
Hospitals, group purchasing organizations and other health care stakeholders want Congress to do away with pricing confidentiality clauses in purchase contracts for implantable devices, but industry wants to maintain its ability to keep device prices secret.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.